Valneva to Participate in Three Investor Conferences in June 2026
Valneva Laboratories announced on Thursday its participation in several investor conferences in June 2026 in the United States and Europe. The management will present its commercial strategy and portfolio of vaccine candidates, particularly LB6V, its candidate against Lyme disease developed in partnership with Pfizer.
Valneva will hold individual meetings and collective presentations at three major events. The group will participate in the Jefferies Global Healthcare Conference (June 3, 11:40 AM ET in New York) with a 'fireside chat' interview format, which will be available via webcast, at the Oddo BHF Nextcap forum (June 12, virtual format), and at the BNP Paribas SMID Cap conference (June 24 in Paris). Institutional investors wishing to meet with the management can submit a request through their respective representatives.
Participation as a Sponsor at a European Medical Conference
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Valneva will also enhance its presence among travel medicine professionals at the 10th Northern European Conference on Travel Medicine (NECTM10), which will be held from June 3 to 5 in Belfast. The group is listed as a gold sponsor and exhibitor, with a dedicated booth (booth 4). A thematic session titled 'From Risk to Protection: Real-World Perspectives on Mosquito-Borne Diseases' is scheduled for June 5 at 12:30 PM BST.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T1 2026
Key reported figures
Revenue: 30,9 millions d'euros
Quarterly revenue: 30,9 millions d'euros
Revenue growth: -37,2 %
EBITDA: -18,2 millions d'euros
Net income: -32,1 millions d'euros
Free cash flow: 0,3 millions d'euros
Risks mentioned
Baisse des ventes de produits de tiers reflétée dans les résultats.
Tendances défavorables dans l'adoption des vaccins du voyage.
Opportunities identified
Concentration des ressources sur les projets stratégiques clés.
Outlook / guidance
Expected revenue: 152,5 millions d'euros
Management commentary: La Société prévoit désormais des ventes de produits situées entre 135 millions d'euros et 150 millions d'euros, contre 145 millions d'euros à 160 millions d'euros précédemment Les autres revenus sont confirmés – conduisant à une nouvelle prévision de chiffre d'affaires située entre 145 millions d'euros et 160 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
